Virus-like particles as vaccines for paramyxovirus

1. A recombinant virus-like particle (VLP) comprising, in operable combination:

a) a Newcastle disease virus matrix (M) protein,

b) a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

c) a Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

d) a type 1 protein of interest, and

e) an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein,

wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said type 1 protein of interest, and wherein said HR2 domain protein is flanked by said type 1 protein of interest and by said F protein TM.

2. A method for producing a VLP comprising a protein, comprising:

a) providing an expression vector comprising, in operable combination:

1) a first nucleic acid sequence encoding a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

2) a second nucleic acid sequence encoding Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

3) a third nucleic acid sequence encoding a type 1 protein of interest, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and

4) a fourth nucleic acid sequence encoding Newcastle Disease virus matrix (M) protein, and

5) a fifth nucleic acid sequence encoding an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein, wherein said fifth nucleic acid sequence is flanked by said third nucleic acid sequence encoding said type 1 protein of interest and by said first nucleic acid sequence encoding said Newcastle disease virus F protein TM,

b) providing a host cell, and

c) transfecting said host cell with said vector to produce virus-like particles (VLPs) comprising said type 1 protein of interest.

3. A method for producing a VLP comprising a protein, comprising:

a) providing a first expression vector comprising, in operable combination:

1) a first nucleic acid sequence encoding a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

2) a second nucleic acid sequence encoding Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

3) a third nucleic acid sequence encoding a type 1 protein of interest, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and

4) a fourth nucleic acid sequence encoding an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein, wherein said fourth nucleic acid sequence is flanked by said third nucleic acid sequence encoding said type 1 protein of interest and by said first nucleic acid sequence encoding said Newcastle disease virus F protein TM,

b) providing a second expression vector comprising a fifth nucleic acid sequence encoding Newcastle Disease virus matrix (M) protein,

c) providing a host cell, and

d) transfecting said host cell with said first and second vectors to produce virus-like particles (VLPs) comprising said type 1 protein of interest.

4. A method for producing a Respiratory Syncytial virus (RSV) ectodomain protein, comprising

a) providing an expression vector comprising, in operable combination,

1) a first nucleic acid sequence encoding a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

2) a second nucleic acid sequence encoding Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

3) a third nucleic acid sequence encoding a Respiratory Syncytial virus (RSV) fusion (F) protein ectodomain protein, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences,

4) a fourth nucleic acid sequence encoding Newcastle Disease virus matrix (M) protein, and

5) a fifth nucleic acid sequence encoding an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein,. wherein said fifth nucleic acid sequence is flanked by said third nucleic acid sequence encoding said RSV F protein ectodomain and by said first nucleic acid sequence encoding said Newcastle disease virus F protein TM,

b) providing a target host cell, and

c) transfecting said target host cell with said vector to produce a transfected host cell that produces virus-like particles (VLPs) that comprise said RSV ectodomain protein.

5. A method for producing a Respiratory Syncytial virus (RSV) ectodomain protein, comprising

a) providing a first expression vector comprising, in operable combination,

1) a first nucleic acid sequence encoding a Newcastle disease virus Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

2) a second nucleic acid sequence encoding Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

3) a third nucleic acid sequence encoding a Respiratory Syncytial virus (RSV) fusion (F) protein ectodomain protein, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and

4) a fourth nucleic acid sequence encoding an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein, wherein said fourth nucleic acid sequence is flanked by said third nucleic acid sequence encoding said RSV F protein ectodomain and by said first nucleic acid sequence encoding said Newcastle disease virus F protein TM,

b) providing a second expression vector comprising a fifth nucleic acid sequence encoding Newcastle Disease virus matrix (M) protein,

c) providing a target host cell, and

d) transfecting said target host cell with said first and second vectors to produce a transfected host cell that produces virus-like particles (VLPs) that comprise said RSV ectodomain protein.

6. A method for immunizing an animal against Respiratory Syncytial Virus, comprising

a) providing

1) a VLP vaccine comprising, in operable combination

i) a Newcastle disease virus matrix (M) protein,

ii) a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

iii) a Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

iv) a Respiratory Syncytial virus (RSV) fusion (F) protein ectodomain protein, and

v) an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein, wherein said HR2 domain protein is flanked by said RSV F protein ectodomain protein and by said Newcastle disease virus TM,

wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said ectodomain protein, and

2) an animal, and

b) administering said vaccine to said animal to produce an immune response against said Respiratory Syncytial virus.

7. The method of claim 6 , wherein said administering is intramuscular.

8. The method of claim 7 , wherein said administering is in a single dose.

9. The method of claim 7 , wherein said administering comprises 10 microgram of said VLP.

10. A virus-like particle (VLP) comprising, in operable combination

a) a Newcastle disease virus matrix (M) protein,

b) a Newcastle disease virus fusion (F) protein transmembrane domain (TM) protein,

c) a Newcastle Disease virus fusion (F) protein cytoplasmic domain (CT) protein,

d) human Respiratory Syncytial virus (RSV) G protein ectodomain,

e) human RSV F protein ectodomain,

f) an amino acid sequence consisting of Newcastle Disease virus HR2 domain protein,

g) Newcastle disease virus haemagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein, and

h) Newcastle Disease virus haemagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein,

wherein said Newcastle disease virus F protein transmembrane (TM) protein is flanked by said Newcastle disease virus F protein cytoplasmic domain (CT) protein and by said RSV F protein ectodomain protein, wherein said Newcastle disease virus HN TM protein is flanked by said Newcastle disease virus HN CT protein and by said RSV G protein ectodomain, and wherein said HR2 domain protein is flanked by said type 1 protein of interest and said transmembrane (TM) protein.

11. The VLP of claim 1 , further comprising Newcastle disease virus nucleocapsid (NP) protein.

12. The method of claim 2 , wherein said expression vector further comprises a sixth nucleic acid sequence encoding Newcastle disease virus nucleocapsid (NP) protein.

13. The method of claim 3 , wherein said first expression vector further comprises a sixth nucleic acid sequence encoding Newcastle disease virus nucleocapsid (NP) protein.

14. The method of claim 3 , wherein said second expression vector further comprises a sixth nucleic acid sequence encoding Newcastle disease virus nucleocapsid (NP) protein.

15. The VLP of claim 1 , further comprising

f) Newcastle disease virus hemagglutinin-neuraminidase (HN) transmembrane domain (TM) protein,

g) Newcastle Disease virus hemagglutinin-neuraminidase (HN) cytoplasmic domain (CT) protein, and

h) type 2 protein of interest,

wherein said HN TM protein is flanked by said HN CT protein and said type 2 protein of interest.

16. The method of claim 2 , wherein said expression vector further comprises

6) a sixth nucleic acid sequence encoding Newcastle disease virus hemagglutinin-neuraminidase (HN) transmembrane domain (TM) protein,

7) a seventh nucleic acid sequence encoding Newcastle Disease virus hemagglutinin-neuraminidase (HN) cytoplasmic domain (CT) protein, and

8) an eighth nucleic acid sequence encoding a type 2 protein of interest,

wherein said sixth nucleic acid sequence is flanked by said seventh and eighth nucleic acid sequences.